Singapore
Project EISE serves as a bridge between private and public sector partners within the multi-stakeholder cancer ecosystem.
The company has established collaborations with several vaccine development companies, including the San Diego-based Arcturus which is running clinical trials in Singapore.
The startup has currently 15,000 users for its MyCLNQ app and plans to expand regionally in the next two years.
Users can also access digital Medical Certificates (MC), clinic invoices and laboratory results from the clinics visited securely through the app.
For the next three years, Holmusk will work with Singapore’s HPB to offer a phone coaching program to children and youths who are severely overweight and/or have abnormal health screening results.
The study indicated that the reagent used in Lucence’s SAFER Sample saliva collection kit inactivates SARS-CoV-2 within 45 seconds of sample collection.
The first batch of these devices will be delivered in the later half of this month, said Vivian Balakrishnan, Minister-in-charge of the Smart Nation initiative.
This follows the Singapore-based startup’s undisclosed amount of Series B funding in January 2020.
Researchers from SMART’s AMR IRG, NTU and MIT are working together to develop a rapid serological test and a rapid diagnostic test (RDT), based on protein detection.
Professor Wang Linfa, Director of the Duke-NUS’ Emerging Infectious Diseases programme, and team conceived this research and invented the cPass diagnostic test.